BRIEF published on 05/11/2026 at 08:05, 4 months 13 days ago Pentixapharm Submits IND to FDA for Phase 3 PANDA Study Pentixapharm Precision Diagnostics FDA IND Submission Phase 3 PANDA Cardiovascular Imaging
PRESS RELEASE published on 05/11/2026 at 08:00, 4 months 13 days ago Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic Pentixapharm submits IND to FDA for Phase 3 PANDA study of CXCR4-targeted cardiovascular diagnostic, aiming at precision diagnostics in primary aldosteronism Pentixapharm IND Submission Phase 3 PANDA Study CXCR4-targeted Cardiovascular Diagnostic
BRIEF published on 05/07/2026 at 08:05, 4 months 17 days ago Point sur le développement financier et clinique de Pentixapharm au premier trimestre 2026 Résultats Financiers Développement Clinique Gestion Des Coûts Produits Radiopharmaceutiques Commentaires Réglementaires
BRIEF published on 05/07/2026 at 08:05, 4 months 17 days ago Pentixapharm Q1 2026 Financial and Clinical Development Update Financial Results Clinical Development Radiopharmaceuticals Cost Management Regulatory Feedback
PRESS RELEASE published on 05/07/2026 at 08:00, 4 months 17 days ago Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum Pentixapharm Holding AG reports Q1 2026 financial results, highlights progress in clinical and regulatory activities, and provides full-year financial guidance Financial Results Regulatory Pentixapharm Q1 2026 Clinical
BRIEF published on 03/31/2026 at 08:05, 5 months 24 days ago Pentixapharm Holding AG nomme Erik Merten au conseil d'administration Conseil D'administration Produits Radiopharmaceutiques Pentixapharm Erik Merten Programme PANDA
BRIEF published on 03/31/2026 at 08:05, 5 months 24 days ago Pentixapharm Holding AG Appoints Erik Merten to Executive Board Executive Board Radiopharmaceuticals Pentixapharm Erik Merten PANDA Program
PRESS RELEASE published on 03/31/2026 at 08:00, 5 months 24 days ago Pentixapharm Holding AG Appoints Erik Merten to the Executive Board Pentixapharm Holding AG appoints Erik Merten as Chief Technology Officer (CTO) to enhance radiopharmaceutical development and manufacturing capabilities, supporting Phase 3 PANDA program and future commercialization Executive Board Radiopharmaceuticals Pentixapharm Holding AG Erik Merten Phase 3 PANDA Program
BRIEF published on 03/19/2026 at 10:19, 6 months 5 days ago Pentixapharm Holding AG to Reveal 2025 Financial Results Conference Call Clinical Trials Pentixapharm Radiotherapeutics 2025 Financial Results
BRIEF published on 03/19/2026 at 10:19, 6 months 5 days ago Pentixapharm Holding AG publiera ses résultats financiers pour 2025 Conférence Téléphonique Essais Cliniques Pentixapharm Radiothérapie Résultats Financiers De 2025
Published on 09/24/2026 at 22:01, 1 hour 56 minutes ago Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 14:55, 9 hours 2 minutes ago Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/24/2026 at 14:30, 9 hours 27 minutes ago Solitario Resources CEO to Present at the 38th Annual Mining Forum Americas 2026 Conference
Published on 09/24/2026 at 14:00, 9 hours 57 minutes ago Horizon Aircraft to Report First Quarter 2027 Results and Provide a Business Update on October 9, 2026
Published on 09/24/2026 at 20:29, 3 hours 28 minutes ago EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 4 hours 57 minutes ago HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 5 hours 16 minutes ago EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares
Published on 09/24/2026 at 18:15, 5 hours 42 minutes ago Epanko Value Engineering Identifies 20% Production Increase
Published on 09/24/2026 at 18:05, 5 hours 52 minutes ago DCK Tools Showcases Expanded Outdoor Power Equipment Lineup at Salonvert 2026
Published on 09/24/2026 at 18:31, 5 hours 26 minutes ago LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:00, 5 hours 57 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 5 hours 57 minutes ago GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
